Latest News and Press Releases

CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...

Began dosing of TC-210 in the Phase 1/2 trial for patients with mesothelin-expressing solid tumors and an interim update anticipated in 4Q19/1Q20Leading clinical sites participating in the TC-210...

CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...

Expansion of leadership team to support clinical trials with an emphasis on manufacturing, IND enablement and development of next generation of TRuC-T cells CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE...

CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...

CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...

Initiated Phase 1/2 clinical trial for TC-210, TCR2’s lead product candidate targeting mesothelin expressing solid tumorsOn track to file an IND for TCR2’s lead hematology product candidate, TC-110,...

Preclinical study results published in Nature Communications show superior anti-tumor activity of T cell receptor fusion construct T cells (TRuC™)-T cells compared to chimeric antigen receptor (CAR)-T...

Earnings to be released after market close on Monday, May 13, 2019 CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (TCR2) (Nasdaq: TCRR), a clinical-stage immunotherapy...